Kerry acquires LactoSens Biosensor technology to enhance lactose-free dairy solutions

UK – Kerry has acquired DirectSens’ LactoSens technology, a rapid and cost-effective lactose detection solution, further strengthening its offering in the dairy sector. 

The acquisition aligns with Kerry’s lactase enzyme solutions, enabling a more integrated package for food manufacturers.

LactoSens, widely used in food and beverage production, facilitates real-time lactose analysis, helping producers meet regulatory standards while optimizing processes. 

The technology offers various advantages, including faster product release, batch traceability, ease of use, and specificity, with no interference from other sugars or ingredients like chocolate and coffee. It is also validated against the industry-standard HPLC method.

In its Q3 2024 financial report, Kerry emphasized that while the acquisition is modest in scale, it enhances its ability to deliver comprehensive solutions for lactose-free dairy products. 

This reflects the growing demand for lactose-free and sugar-reduced offerings driven by rising awareness of lactose intolerance and health-conscious consumption.

This move builds on Kerry’s broader strategy in enzyme technology. In December 2023, Kerry agreed to acquire parts of the global lactase enzyme business from Chr. Hansen and Novozymes for €150 million, pending regulatory approval.

These enzymes, which include NOLA products, further Kerry’s capability in producing lactose-free dairy products while maintaining authentic taste.

The lactase enzyme business reported revenues of €40 million in 2022, with sales across 50 countries. 

Following its recent acquisitions of c-LEcta and Enmex, Kerry continues to expand its biotechnology solutions, positioning itself as a leader in the fast-growing lactose-free dairy segment.

Subscribe to our food and agriculture industry email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE